Rossari Biotech Limited (NSE:ROSSARI)
India · Delayed Price · Currency is INR | Market Cap | 30.13B -20.1% |
| Revenue (ttm) | 23.96B +15.2% |
| Net Income | 1.49B +9.4% |
| EPS | 26.93 +9.3% |
| Shares Out | 55.39M |
| PE Ratio | 20.20 |
| Forward PE | 19.09 |
| Dividend | 0.50 (0.09%) |
| Ex-Dividend Date | Jun 20, 2025 |
| Volume | 85,400 |
| Average Volume | 463,174 |
| Open | 537.35 |
| Previous Close | 544.00 |
| Day's Range | 520.95 - 537.35 |
| 52-Week Range | 375.00 - 766.00 |
| Beta | 0.50 |
| RSI | 62.67 |
| Earnings Date | Apr 27, 2026 |
About Rossari Biotech
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing li... [Read more]
Financial Performance
In fiscal year 2026, Rossari Biotech's revenue was 23.96 billion, an increase of 15.19% compared to the previous year's 20.80 billion. Earnings were 1.49 billion, an increase of 9.41%.
Financial StatementsNews
Rossari Biotech Ltd (BOM:543213) Q4 2026 Earnings Call Highlights: Record Revenue Amidst Margin ...
Rossari Biotech Ltd (BOM:543213) Q4 2026 Earnings Call Highlights: Record Revenue Amidst Margin Pressures
Q4 2026 Rossari Biotech Ltd Earnings Call Transcript
Q4 2026 Rossari Biotech Ltd Earnings Call Transcript
Rossari Biotech Transcript: Q4 25/26
Q4 and FY 2026 saw record revenue and EBITDA, with 15% annual growth driven by all segments and strong exports. FY 2027 guidance targets similar or higher growth and 12%-13% EBITDA margins, supported by new capacities, product mix improvements, and cost optimization.
Rossari Biotech subsidiary approves Rs 10 crore sale of Mumbai office premises
Rossari Biotech's material subsidiary, Unitop Chemicals Private Limited, has approved the sale of its office premises located in Saki Naka, Mumbai. The transaction, valued at approximately ₹10 crores,...
Rossari Biotech Ltd (BOM:543213) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ...
Rossari Biotech Ltd (BOM:543213) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst Challenges
Q3 2026 Rossari Biotech Ltd Earnings Call Transcript
Q3 2026 Rossari Biotech Ltd Earnings Call Transcript
Rossari Biotech Transcript: Q3 25/26
Q3 FY26 saw 13% YoY revenue growth, led by strong export performance and broad-based segment gains, though margins were impacted by ongoing investments and B2C weakness. New capacities and global expansion, especially in Saudi Arabia, are set to drive future growth and margin improvement.
Rossari Biotech Ltd (BOM:543213) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Rossari Biotech Ltd (BOM:543213) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Pricing Pressures
Q2 2026 Rossari Biotech Ltd Earnings Call Transcript
Q2 2026 Rossari Biotech Ltd Earnings Call Transcript
Rossari Biotech Transcript: Q2 25/26
Q2 FY 2026 saw 18% revenue growth, led by strong volumes across all core segments and robust export gains, though margins softened due to pricing pressures and one-time expenses. Capacity expansions and new product launches support a positive outlook, but global tariffs and working capital stretch pose risks.
Rossari Biotech Transcript: Q1 25/26
Q1 FY26 saw 11% YoY revenue growth, led by HPPC and AHN, with EBITDA margin at 12.5%. Capacity expansions and international initiatives are underway, with mid-double-digit growth and margin improvement expected as new facilities ramp up and export headwinds ease.
Rossari Biotech Transcript: Q4 24/25
FY 2025 delivered 13.6% revenue growth and stable margins, driven by HPPC and new verticals, with strong export momentum. CapEx of INR 192 crores will expand capacity and support innovation, while margin improvement is expected as new businesses scale.
Rossari Biotech’s subsidiary wins GST appeal; previous tax order set aside
Rossari Biotech Limited has announced that its subsidiary, Unitop Chemicals Private Limited, has successfully won an appeal against a GST Order issued by the Joint Commissioner, Central GST & Central ...
Rossari Biotech Ltd (BOM:543213) Q3 2025 Earnings Call Highlights: Strong Export Growth and ...
Rossari Biotech Ltd (BOM:543213) Q3 2025 Earnings Call Highlights: Strong Export Growth and Capacity Expansion Drive Performance
Q3 2025 Rossari Biotech Ltd Earnings Call Transcript
Q3 2025 Rossari Biotech Ltd Earnings Call Transcript
Rossari Biotech Transcript: Q3 24/25
Q3 FY25 saw 10.5% YOY revenue growth to INR 512.7 crore, led by strong exports and improved gross margins, though EBITDA margin declined due to higher costs from expansion and hiring. Capacity additions and export growth are expected to drive future performance, with EO supply a key risk.
Rossari Biotech stock drops 4.28% following Q2 results
Rossari Biotech saw its stock price fall by 4.28%, trading at ₹838.35 as of 9:35 AM today. The drop follows the company’s release of its Q2 FY24-25 earnings, which failed to meet market expectations. ...